Valuation: Nuvectra Corporation

Market Cap 1.7M 1.52M 1.4M 1.27M 2.37M 161M 2.42M 16.69M 6.7M 84.86M 6.38M 6.24M 268M P/E 2017
-1.84x
P/E 2018 -5.02x
Enterprise Value -53.46M -47.88M -44.04M -39.9M -74.59M -5.08B -75.99M -525M -211M -2.67B -201M -196M -8.42B EV / Sales 2017
2.58x
EV / Sales 2018 4.76x
Free-Float
96.76%
Yield 2017 *
-
Yield 2018 -
Manager TitleAgeSince
Chief Executive Officer 78 31/01/2019
Compliance Officer 51 01/01/2015
Director TitleAgeSince
Director/Board Member 67 01/03/2016
Director/Board Member 78 01/03/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+16.67% - - 268K
+1.56%+2.41%-14.09%+12.32% 184B
-0.59%+1.18%+6.44%+36.82% 118B
-6.38%-4.98%-18.07%+8.01% 111B
+3.42%+1.71%-41.92%+8.01% 94.58B
+0.09%-0.05%-2.06%+78.69% 63.13B
-0.46%+0.42%+4.48%+82.84% 55.66B
-0.23%-0.52%+10.73%-21.72% 53.9B
-4.30%-1.64%-12.44%+37.99% 43.42B
+0.58%+2.00%-1.17%-8.82% 34.68B
Average -0.63%+1.72%-7.57%+26.01% 75.84B
Weighted average by Cap. -0.48%+0.24%-10.13%+23.75%

Financials

2017 2018
Net sales 31.84M 28.51M 26.23M 23.76M 44.42M 3.02B 45.25M 313M 126M 1.59B 119M 117M 5.01B 48.83M 43.73M 40.23M 36.45M 68.13M 4.64B 69.41M 480M 193M 2.44B 183M 179M 7.69B
Net income -44.6M -39.94M -36.74M -33.29M -62.23M -4.23B -63.39M -438M -176M -2.23B -167M -164M -7.03B -48.13M -43.11M -39.65M -35.93M -67.16M -4.57B -68.41M -473M -190M -2.4B -181M -177M -7.58B
Net Debt -1.49M -1.33M -1.23M -1.11M -2.08M -141M -2.12M -14.64M -5.88M -74.42M -5.59M -5.47M -235M -55.16M -49.4M -45.44M -41.17M -76.96M -5.24B -78.4M -542M -218M -2.75B -207M -203M -8.69B
Logo Nuvectra Corporation
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
Employees
-
  1. Stock Market
  2. Stocks
  3. NVTRQ Stock